Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
J2H-2302
- Development stage
- Preclinical
- Lead developer
- J2H Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
J2H-2302 is an oral fixed-dose combination (FDC) small molecule therapy under development by J2H Biotech for the treatment of idiopathic pulmonary fibrosis (IPF) and radiation-induced pulmonary fibrosis (RIPF). It combines J2H-1702, a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, with nintedanib, an approved multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR. This combination approach is designed to synergistically suppress fibrotic pathways, protect lung tissue, and potentially reduce the adverse effects and improve the tolerability associated with nintedanib monotherapy. J2H-2302 is currently in preclinical development.
- Other names
- J2H-1702 + nintedanibJ2H-1702 FDCJ-2H-1702 FDCJ 2H-1702 FDC
02
Targets
HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on J2H-2302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J2H-2302.